Verrica Pharmaceuticals Reports Positive Preliminary Topline Results from Part 2 of Phase 2 VP-315 Clinical Study

August 14, 2024

DENVER, Colo., Aug 14, 2024 (247marketnews.com)- Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported preliminary positive results from the second part of its Phase 2 clinical trial studying VP-315 for basal cell carcinoma treatment.

Ted White, President and CEO, stated, “We believe the positive results from Part 2 of the Phase 2 study for VP-315 are a meaningful step forward in potentially providing basal cell carcinoma patients with additional treatment options.

“We are encouraged by our preliminary results, which we believe support the use of VP-315 as a first line therapy for use in both a primary and neoadjuvant setting. We believe VP-315 has the potential to be a multi-billion dollar commercial opportunity for Verrica.”

Verrica’s Chief Medical Officer, Dr. Gary Goldenberg, added, “Basal cell carcinoma is the most common form of cancer in the U.S. and current therapies have drawbacks, including systemic side-effects.

“The preliminary results from Part 2 of the trial show greater than 50% complete histological clearance and a significant reduction in tumor size for tumors treated in the study, which we believe has the potential to vastly improve patient outcomes versus current therapies and surgical procedures. In addition, given the immunomodulatory properties of VP-315, we are also excited to continue to explore these properties in tissue and blood samples.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (VRCA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.